Talphera Investor Relations Material
Latest events
Q4 2023
Talphera
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Talphera Inc
Access all reports
Talphera Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA™ (sufentanil sublingual tablet, 30 mcg) which has completed Phase 3 trials. The Company believes that DSUVIA is a potential first-in-class non-invasive treatment option that can deliver rapid relief to patients suffering from moderate to severe acute pain.
Latest articles
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States